The patent has been granted The patent has been granted, Grant of patent is intended, Request for examination was made, The application has been published EP Register Verified

FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY

Publication No. EP4403579

•

App No. EP24167554

•

Filed by Millennium Pharmaceuticals, Inc.

•

Filed on 2012-05-02

•

Issued/Published on 2025-12-10

Official EPO Register

Publication No. EP4403579 A2

Application No. EP24167554 Filed: 2012-05-02

Grant Date 2025-12-10 Mention of grant

Active Oppositions 5 Active EPO Oppositions

Patent Abstract / Summary

[0001] Antibody formulations are described comprising a mixture of an anti-α4β7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.

IPC Classifications

A61K39/395, A61K47/12, A61K47/14, A61K47/18, A61K47/26, A61K9/00, A61P1/00, A61P1/04, A61P1/16, A61P1/18, A61P3/10, A61P29/00, A61P31/18, A61P37/06, A61P43/00 A61K39/395, A61K47/12, A61K47/14, A61K47/18, A61K47/26, A61K9/00 C07K16/28

Priority Claims

US 201161481522P Date: 2011-05-02

US 201161544054P Date: 2011-10-06

Designated Contracting States (38 EPC States)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Parties & Representation

Applicants

Millennium Pharmaceuticals, Inc.

40 Landsdowne Street, Cambridge, MA 02139

Inventors (9)

DILUZIO, Willow

Gloucester MA, 01930

NGUYEN, Phuong M.

Cambridge, MA, 02141

VARGA, Csanad M.

Newton, MA, 02459

PALANIAPPAN, Vaithianathan

Andover, MA, 01810

BROWN, Jason

Burlington, MA, 01803

FOX, Irving H.

Dedham, MA, 02026

SCHOLZ, Catherine

North Reading, MA, 01864

JENKINS, Erica Helen

Cottenham, Cambridgeshire, CB24 8RB

ROSARIO, Maria

Mystic, CT, 06355

Representatives / Agents

Carpmaels & Ransford LLP

One Southampton Row, London WC1B 5HA

Hoffmann Eitle

Patent- und Rechtsanwälte PartmbB, Arabellastraße 30

Abel & Imray LLP

20 St. Andrew Street, London EC4A 3AG

Graf von Stosch, Andreas

Graf von Stosch, Patentanwaltsgesellschaft mbH

D Young & Co LLP

3 Noble Street, London EC2V 7BQ

Reddie & Grose LLP

Reddie & Grose GmbH The White Chapel Building, 10 Whitechapel High Street

Elkington and Fife LLP

Prospect House, 8 Pembroke Road

Key Procedural Dates

Request-For-Examination 2025-04-11

Mention Of Grant Published 2025-12-10

First-Examination-Report-Despatched 2025-07-21

Patent Oppositions

Official opposition proceedings filed against European Patent EP4403579 under EPC Article 99.

5 ACTIVE OPPONENTS

Opponent Company

Abel & Imray LLP

20 St. Andrew Street, GB

Representative

Abel & Imray LLP

Filing Date

2026-09-04

Opposition in Progress

Opponent Company

Lepthien, Sandra

c/o Graf von Stosch Patentanwaltsgesellschaft, DE

Representative

Graf von Stosch, Andreas

Filing Date

2026-09-09

Opposition in Progress

Opponent Company

Fresenius Kabi SwissBiosim GmbH

Terre Bonne Business Park / Route de Crassier, CH

Representative

D Young & Co LLP

Filing Date

2026-09-09

Opposition in Progress

Opponent Company

Camulon Ltd

The Whitechapel Building, GB

Representative

Reddie & Grose LLP

Filing Date

2026-09-10

Opposition in Progress

Opponent Company

Advanz Pharma Services (UK) Ltd

UK (Corporate Headquarters), GB

Representative

Elkington and Fife LLP

Filing Date

2026-09-10

Opposition in Progress

Legal Status & Event History

Official European Patent Office legal and procedural status changes recorded for this file.

70 Events Recorded

Date	Code	Event Description	Auth
2024-07-24	AC	DIVISIONAL APPLICATION: REFERENCE TO EARLIER APPLICATION	EP
2024-07-24	AK	DESIGNATED CONTRACTING STATES	EP
2024-06-20	PUAI	PUBLIC REFERENCE MADE UNDER ARTICLE 153(3) EPC TO A PUBLISHED INTERNATIONAL APPLICATION THAT HAS ENTERED THE EUROPEAN PHASE	EP
2024-06-20	STAA	INFORMATION ON THE STATUS OF AN EP PATENT APPLICATION OR GRANTED EP PATENT	EP
2024-09-13	PUAL	SEARCH REPORT DESPATCHED	EP
2024-09-11	REG	REFERENCE TO A NATIONAL CODE	EP
2024-10-16	RIC1	INFORMATION PROVIDED ON IPC CODE ASSIGNED BEFORE GRANT	EP
2024-10-16	AK	DESIGNATED CONTRACTING STATES	EP
2025-03-07	REG	REFERENCE TO A NATIONAL CODE	EP
2025-04-18	STAA	INFORMATION ON THE STATUS OF AN EP PATENT APPLICATION OR GRANTED EP PATENT	EP
2025-05-21	17P	REQUEST FOR EXAMINATION FILED	EP
2025-07-23	RIC1	INFORMATION PROVIDED ON IPC CODE ASSIGNED BEFORE GRANT	EP
2025-07-21	GRAP	DESPATCH OF COMMUNICATION OF INTENTION TO GRANT A PATENT	EP
2025-07-21	STAA	INFORMATION ON THE STATUS OF AN EP PATENT APPLICATION OR GRANTED EP PATENT	EP
2025-08-20	INTG	INTENTION TO GRANT ANNOUNCED	EP
2025-11-07	GRAA	(EXPECTED) GRANT	EP
2025-11-04	GRAS	GRANT FEE PAID	EP
2025-11-07	STAA	INFORMATION ON THE STATUS OF AN EP PATENT APPLICATION OR GRANTED EP PATENT	EP
2025-12-10	RIN1	INFORMATION ON INVENTOR PROVIDED BEFORE GRANT (CORRECTED)	EP
2025-12-10	AC	DIVISIONAL APPLICATION: REFERENCE TO EARLIER APPLICATION	EP
2025-12-10	AK	DESIGNATED CONTRACTING STATES	EP
2025-12-10	REG	REFERENCE TO A NATIONAL CODE	EP
2025-12-24	REG	REFERENCE TO A NATIONAL CODE	EP
2025-12-24	P01	OPT-OUT OF THE COMPETENCE OF THE UNIFIED PATENT COURT (UPC) REGISTERED	EP
2025-12-31	REG	REFERENCE TO A NATIONAL CODE	EP
2026-01-28	REG	REFERENCE TO A NATIONAL CODE	EP
2026-02-04	REG	REFERENCE TO A NATIONAL CODE	EP
2026-02-02	REG	REFERENCE TO A NATIONAL CODE	EP
2012-05-02	REG	REFERENCE TO A NATIONAL CODE	EP
2026-02-16	REG	REFERENCE TO A NATIONAL CODE	EP
2026-02-25	REG	REFERENCE TO A NATIONAL CODE	EP
2026-02-27	REG	REFERENCE TO A NATIONAL CODE	EP
2026-02-05	REG	REFERENCE TO A NATIONAL CODE	EP
2026-03-25	REG	REFERENCE TO A NATIONAL CODE	EP
2026-04-09	PGFP	ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-04-15	REG	REFERENCE TO A NATIONAL CODE	EP
2026-04-08	REG	REFERENCE TO A NATIONAL CODE	EP
2026-05-18	PGFP	ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-05-18	PG25	LAPSED IN A CONTRACTING STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-04-28	REG	REFERENCE TO A NATIONAL CODE	EP
2026-06-01	REG	REFERENCE TO A NATIONAL CODE	EP
2026-05-22	REG	REFERENCE TO A NATIONAL CODE	EP
2026-07-03	PGFP	ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-07-08	PGFP	ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-07-09	PGFP	ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-07-10	PGFP	ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-07-11	PGFP	ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-07-14	PGFP	ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-07-15	PGFP	ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-07-16	PGFP	ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-07-17	PGFP	ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-07-18	PGFP	ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-07-21	PGFP	ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-07-23	PGFP	ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-07-24	PGFP	ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-07-25	PGFP	ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-07-28	PGFP	ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-07-29	PGFP	ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-07-31	PGFP	ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-08-15	REG	REFERENCE TO A NATIONAL CODE	EP
2026-09-11	PLBI	OPPOSITION FILED	EP
2026-09-12	PGFP	ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO]	EP
2026-09-16	REG	REFERENCE TO A NATIONAL CODE	EP
2026-09-18	PLBI	OPPOSITION FILED	EP
2026-09-18	PLAB	OPPOSITION DATA, OPPONENT'S DATA OR THAT OF THE OPPONENT'S REPRESENTATIVE MODIFIED	EP
2026-09-21	PLAX	NOTICE OF OPPOSITION AND REQUEST TO FILE OBSERVATION + TIME LIMIT SENT	EP
2026-09-04	REG	REFERENCE TO A NATIONAL CODE	EP
2026-09-23	REG	REFERENCE TO A NATIONAL CODE	EP
2026-10-14	26	OPPOSITION FILED	EP
2026-10-20	PLAF	INFORMATION MODIFIED RELATED TO COMMUNICATION OF A NOTICE OF OPPOSITION AND REQUEST TO FILE OBSERVATIONS + TIME LIMIT	EP

Patent & Non-Patent Citations

Cited documents and prior art referenced in search and examination reports.

53 Citations

Cited Patent Documents

WO2007061679 2007-05-31

Espacenet

WO2009099641 2009-08-13

Espacenet

US2005095238 2005-05-05

Espacenet

US61481522

Espacenet

US61544054

Espacenet

WO2012151247

Espacenet

WO2012151248

Espacenet

WO2007092772

Espacenet

US2010254975

Espacenet

WO2011147921

Espacenet

WO9937329

Espacenet

WO2010066762

Espacenet

WO2004091658

Espacenet

Non-Patent Scientific Literature (NPL)

- DATABASE Pubchem 26 August 2025 (2025-08-26), PUBCHEM: "Vedolizumab", XP093435538, Database accession no. SID 481101896

- ANONYMOUS: "Vedolizumab Drugbank ID DB09033", HTTPS://GO.DRUGBANK.COM, OMX PERSONAL HEALTH ANALYTICS, INC., 6 March 2025 (2025-03-06), pages 1 - 10, XP093435549, Retrieved from the Internet <URL:https://go.drugbank.com/drugs/DB09033>

- RUTGEERTS, P. ; VERMEIRE, S. ; VAN ASSCHE, G.: "Biological Therapies for Inflammatory Bowel Diseases", GASTROENTEROLOGY, vol. 136, no. 4, 1 April 2009 (2009-04-01), NL, pages 1182 - 1197, XP026070050, ISSN: 0016-5085, DOI: 10.1053/j.gastro.2009.02.001

- ROBERT J FALCONER, CHERRINE CHAN, KAREN HUGHES, TRENT P MUNRO: "Stabilization of a monoclonal antibody during purification and formulation by addition of basic amino acid excipients", JOURNAL OF CHEMICAL TECHNOLOGY & BIOTECHNOLOGY, vol. 86, no. 7, 7 July 2011 (2011-07-07), pages 942 - 948, XP055076799, ISSN: 02682575, DOI: 10.1002/jctb.2657

- WHO DRUG INFORMATION: "International Nonproprietary Names for Pharmaceutical Substances (INN) List 100", HTTPS://WWW.WHO.INT, WHO, vol. 22, no. 4, 9 December 2008 (2008-12-09), pages 1 - 57, XP093435561

- D10 - T0103/20 –RPBA Communication dated 18.10.2022

- D11 - Minutes of the Appeal oral proceedings in respect of T 103/20

- "Formulation and process development strategies for manufacturing biopharmaceuticals.", 26 July 2010, WILEY , New York , ISBN: 9780470118122, article SAMPATHKUMAR KRISHNAN, MONICA M. PALLITTO, MARGARET S. RICCI: "Chapter 16: Development of Formulations for Therapeutic Monoclonal Antibodies and Fc Fusion Proteins", pages: 383 - 427, XP055188652, DOI: 10.1002/9780470595886.ch16

- "Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals", 5 August 2010, article FEROZ JAMEEL AND MIKE J. PIKAL: "chapter 18: DESIGN OF A FORMULATION FOR FREEZE DRYING", XP055188661

- JAMEEL FEROZ ; HERSHENSON SUSAN: "Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals", 26 July 2010, JOHN WILEY & SONS, INC. , Hoboken, N.J. , ISBN: 978-0-470-11812-2, article JAMEEL FEROZ, PADALA CHAKRADHAR, RANDOLPH THEODORE W.: "Strategies for Bulk Storage and Shipment of Proteins", pages: 677 - 704, XP093436607, DOI: 10.1002/9780470595886.ch27 * page 692 - page 694 *

- "Formulation and process development strategies for manufacturing biopharmaceuticals.", 1 January 2010, WILEY , New York , ISBN: 9780470118122, article STEVEN J SHIRE, FRIES, JÜRG, MAHLER: "High-concentration antibody formulations", pages: 349 - 381, XP055050466, DOI: 10.1002/9780470595886.ch15

- JAMEEL FEROZ ; HERSHENSON SUSAN: "Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals", 5 August 2010, JOHN WILEY & SONS, INC. , Hoboken, N.J. , ISBN: 978-0-470-11812-2, article FEROZ JAMEEL, MIKE J. PIKAL: "Chapter 18: Design of a Formulation for Freeze Drying", pages: 457 - 492, XP055188661, DOI: 10.1002/9780470595886.ch18

- WEI WANG , SATISH SINGH, DAVID L ZENG, KEVIN KING, SANDEEP NEMA: "Antibody structure, instability, and formulation", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 96, no. 1, 1 January 2007 (2007-01-01), pages 1 - 26, XP009084505, DOI: 10.1002/jps.20727

- T. ARAKAWA ; K. TSUMOTO ; Y. KITA ; B. CHANG ; D. EJIMA: "Biotechnology applications of amino acids in protein purification and formulations", AMINO ACIDS, vol. 33, no. 4, 16 March 2007 (2007-03-16), AT, pages 587 - 605, XP019565540, ISSN: 1438-2199, DOI: 10.1007/s00726-007-0506-3

- ANONYMOUS: "New Data on the Use of Biologic Agents for Crohn's disease and Ulcerative Colitis: Highlights from the 2009 CCFA Advances in IBD Meeting", GASTROENTEROLOGY & HEPATOLOGY, vol. 6, no. 2,suppl 3, 1 February 2010 (2010-02-01), US , pages 1 - 16, XP055484687, ISSN: 1554-7914

- FEAGAN B, LEACH T, MILCH C, PARIKH A, FOX I: "Emerging Safety Profile of Vedolizumab: A novel, selective Integrin Inhibitor for the treatment of IBD : P-0025.", INFLAMMATORY BOWEL DISEASES, vol. 15, 1 December 2009 (2009-12-01), pages S12, XP093353877, ISSN: 1078-0998, DOI: 10.1097/00054725-200912002-00033

- REICHERT JANICE M.: "Antibodies to watch in 2010", MABS, vol. 2, no. 1, 1 January 2010 (2010-01-01), US , pages 84 - 100, XP055861985, ISSN: 1942-0862, DOI: 10.4161/mabs.2.1.10677

- "Leukocyte Trafficking: Molecular Mechanisms, Therapeutic Targets, and Methods", 7 November 2005, WILEY‐VCH VERLAG GMBH & CO. KGAA, Weinheim, FRG, ISBN: 3-527-31228-5, article BRISKIN MICHAEL J.: "Integrins as Therapeutic Targets for Inflammatory Disease", pages: 338 - 370, XP009564728, DOI: 10.1002/352760779X.ch15

- PARIKH A, T LEACH , I FOX , J XU , M PATELLA , B FEAGAN: "P-146: Long-term clinical experience with vedolizumab for the treatment of inflammatory bowel disease: Results of a phase 2 open-label safety extension study", INFLAMMATORY BOWEL DISEASES, vol. 17, no. Suppl. 1, 1 January 2011 (2011-01-01), pages S56, XP093353846, ISSN: 1078-0998, DOI: 10.1093/ibd/17.supplement1.S56

- ANONYMOUS: "Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease {- Simultaneous Studies to Investigate Novel Therapy for Ulcerative Colitis and Crohn’s Disease -} (January 22, 2009) 2009 Newsroom Takeda Pharmaceutical Company Limited", PRESS RELEASE, TAKEDA PHARMACEUTICAL COMPANY LIMITED, 22 January 2009 (2009-01-22), pages 1 - 2, XP093353896, Retrieved from the Internet <URL:https://web.archive.org/web/20120510160012/http://www.takeda.com/press/article_32376.html>

- FEAGAN B, ET AL: "An ascending dose trial of a humanised a4b7 antibody in ulcerative colitis (UC)", GASTROENTEROLOGY, vol. 118, no. 4, 1 January 2000 (2000-01-01), NL, pages A874, XP009125148, ISSN: 0016-5085

- DAUGHERTY, A.L. ; MRSNY, R.J.: "Formulation and delivery issues for monoclonal antibody therapeutics", ADVANCED DRUG DELIVERY REVIEWS, vol. 58, no. 5-6, 7 August 2006 (2006-08-07), NL, pages 686 - 706, XP024892149, ISSN: 0169-409X, DOI: 10.1016/j.addr.2006.03.011

- HANNS-CHRISTIAN MAHLER, WOLFGANG FRIESS, ULLA GRAUSCHOPF, SYLVIA KIESE: "Protein aggregation: Pathways, induction factors and analysis", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 98, no. 9, 1 September 2009 (2009-09-01), pages 2909 - 2934, XP055321457, DOI: 10.1002/jps.21566

- ANONYMOUS: "GUIDELINE ON THE REQUIREMENTS TO THE CHEMICAL AND PHARMACEUTICAL QUALITY DOCUMENTATION CONCERNING INVESTIGATIONAL MEDICINAL PRODUCTS IN CLINICAL TRIALS", EMA, 1 January 2006 (2006-01-01), pages 1 - 31, XP055762828

- CENTER FOR DRUG EVALUATION AND RESEARCH (CDER) CENTER FOR BIOLOGICS EVALUATION AND RESEARCH (CBER): "Guidance for Industry - Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-derived Products", HTTPS://WWW.FDA.GOV, FDA, 1 November 1995 (1995-11-01), pages 1 - 17, XP093435590, Retrieved from the Internet <URL:https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-and-format-investigational-new-drug-applications-inds-phase-1-studies-drugs-including-well>

- U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION: "Guidance for Industry - INDs for Phase 2 and Phase 3 Studies Chemistry, Manufacturing, and Controls Information", HTTPS://WWW.FDA.GOV, FDA, 1 May 2003 (2003-05-01), pages 1 - 27, XP093435595, Retrieved from the Internet <URL:https://www.fda.gov/regulatory-information/search-fda-guidance-documents/inds-phase-2-and-phase-3-studies-chemistry-manufacturing-and-controls-information>

- D28 - Expert Report of Dr Patapoff

- FDA: "HIGHLIGHTS OF PRESCRIBING INFORMATION HUMIRA", HTTPS://WWW.ACCESSDATA.FDA.GOV, FDA, US, 1 February 2011 (2011-02-01), US, pages 1 - 48, XP093435617, Retrieved from the Internet <URL:https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125057s0215lbl.pdf>

- FDA: "HIGHLIGHTS OF PRESCRIBING INFORMATION SIMPONI", HTTPS://WWW.ACCESSDATA.FDA.GOV, FDA, US, 1 April 2009 (2009-04-01), US, pages 1 - 47, XP093435628, Retrieved from the Internet <URL:https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125289s000lbl.pdf>

- FDA: "Enbrel (etanercept) for subcutaneous injection", HTTPS://WWW.ACCESSDATA.FDA.GOV, FDA, US, 18 November 2010 (2010-11-18), US, pages 1 - 42, XP093435635, Retrieved from the Internet <URL:https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/103795s5415lbl.pdf>

- REICHERT JANICE M: "Antibody-based therapeutics to watch in 2011.", MABS, vol. 3, no. 1, 1 January 2011 (2011-01-01), US , pages 76 - 99, XP002675052, ISSN: 1942-0870, DOI: 10.4161/mabs.3.1.13895

- MARíA VáZQUEZ‐REY; DIETMAR A. LANG: "Aggregates in monoclonal antibody manufacturing processes", BIOTECHNOLOGY AND BIOENGINEERING, vol. 108, no. 7, 20 April 2011 (2011-04-20), US, pages 1494 - 1508, XP071113761, ISSN: 0006-3592, DOI: 10.1002/bit.23155

- KERWIN B.A.: "Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 97, no. 8, 1 August 2008 (2008-08-01), pages 2924 - 2935, XP002787362, DOI: 10.1002/jps.21190

- DANILA GUAGNOZZI, ET AL.: "Natalizumab in the treatment of Crohn's disease", BIOLOGICS: TARGETS AND THERAPY, vol. 2, no. 2, 1 June 2008 (2008-06-01), NZ , pages 275, XP055543602, ISSN: 1177-5475, DOI: 10.2147/BTT.S2935

- D39 - Summary table for experiments described in the patent

- "Antibody Expression and Production", 1 January 2011, article TYTHER RAYMOND; JENKINS NIGEL: "Quality Issues Arising from Post-translational Modification of Recombinant Antibodies", pages: 293 - 303, XP009192400

- NICHOLAS W. WARNE;: "Development of high concentration protein biopharmaceuticals: The use of platform approaches in formulation development", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol. 78, no. 2, 3 March 2011 (2011-03-03), NL , pages 208 - 212, XP028203394, ISSN: 0939-6411, DOI: 10.1016/j.ejpb.2011.03.004

- DATABASE Registry 30 July 2007 (2007-07-30), "Immunoglobulin G1, anti-(human integrin LPAM-1 (lymphocyte Peyer's patch adhesion molecule 1)) (human-Mus musculus heavy chain), disulfide with human-Mus musculus κ-chain, dimer (CA INDE X NAME)", XP093435679, Database accession no. 43609-66-3

- BEI CHEN, RAQUEL BAUTISTA, KWOK YU, GERARDO A. ZAPATA, MICHAEL G. MULKERRIN, STEVEN M. CHAMOW : "Influence of histidine on the stability and physical properties of a fully human antibody in aqueous and solid forms.", PHARMACEUTICAL RESEARCH, vol. 20, no. 12, 1 December 2003 (2003-12-01), DE, pages 1952 - 1960, XP002417746, ISSN: 0724-8741, DOI: 10.1023/B:PHAM.0000008042.15988.c0

- D47 - Auxiliary requests (3 and 9) considered in T0103/20

Worldwide Patent Family

Related applications and patents in the same INPADOC worldwide family.

166 Family Members

Country	Publication Number	Kind	Publication Date	Action
EP	EP4403579A2	A2	2024-07-24	Espacenet
EP	EP4403579A3	A3	2024-10-16	Espacenet
EP	EP4403579B1	B1	2025-12-10	Espacenet
AR	AR086238A1	A1	2013-11-27	Espacenet
AR	AR122749A2	A2	2022-10-05	Espacenet
AU	AU2012250872A1	A1	2013-11-21	Espacenet
AU	AU2012250872B2	B2	2017-07-13	Espacenet
AU	AU2017204192A1	A1	2017-07-13	Espacenet
AU	AU2017204192B2	B2	2019-09-12	Espacenet
AU	AU2019216679A1	A1	2019-09-05	Espacenet
AU	AU2019216679B2	B2	2021-09-23	Espacenet
AU	AU2021225160A1	A1	2021-09-30	Espacenet
AU	AU2021225160B2	B2	2023-12-21	Espacenet
AU	AU2023274233A1	A1	2023-12-21	Espacenet
BR	BR112013028169A2	A2	2017-06-27	Espacenet
CA	CA2834900A1	A1	2012-11-08	Espacenet
CA	CA2834900C	C	2021-03-02	Espacenet
CA	CA3051418A1	A1	2012-11-08	Espacenet
CA	CA3051418C	C	2021-05-18	Espacenet
CL	CL2013003145A1	A1	2014-07-25	Espacenet
CL	CL2017000829A1	A1	2017-12-29	Espacenet
CL	CL2020001579A1	A1	2020-11-06	Espacenet
CN	CN103533959A	A	2014-01-22	Espacenet
CN	CN103533959B	B	2018-06-05	Espacenet
CN	CN107998388A	A	2018-05-08	Espacenet
CN	CN107998388B	B	2023-07-14	Espacenet
CN	CN108969469A	A	2018-12-11	Espacenet
CN	CN108969761A	A	2018-12-11	Espacenet
CO	CO6801648A2	A2	2013-11-29	Espacenet
CR	CR20130556A	A	2014-03-05	Espacenet
CY	CY1119436T1	T1	2018-03-07	Espacenet
DK	DK2704742T3	T3	2017-10-23	Espacenet
DK	DK3311834T3	T3	2026-04-20	Espacenet
DK	DK4403579T3	T3	2026-02-02	Espacenet
DO	DOP2013000252A	A	2013-12-31	Espacenet
EA	EA201391613A1	A1	2014-07-30	Espacenet
EA	EA201391613A8	A8	2016-05-31	Espacenet
EA	EA032625B1	B1	2019-06-28	Espacenet
EA	EA201990056A1	A1	2019-08-30	Espacenet
EC	ECSP13013059A	A	2014-01-31	Espacenet
EC	ECSP22046340A	A	2022-07-29	Espacenet
EP	EP2704742A2	A2	2014-03-12	Espacenet
EP	EP2704742B1	B1	2017-07-12	Espacenet
EP	EP3311834A1	A1	2018-04-25	Espacenet
EP	EP3311834B1	B1	2026-03-11	Espacenet
EP	EP4378959A2	A2	2024-06-05	Espacenet
EP	EP4378959A3	A3	2024-09-04	Espacenet
EP	EP4438625A2	A2	2024-10-02	Espacenet
EP	EP4438625A3	A3	2024-12-11	Espacenet
ES	ES2646717T3	T3	2017-12-15	Espacenet
ES	ES3060110T3	T3	2026-03-25	Espacenet
ES	ES3067483T3	T3	2026-05-22	Espacenet
FI	FI3311834T3	T3	2026-04-23	Espacenet
FI	FI4403579T3	T3	2026-01-28	Espacenet
GE	GEAP201813302A	A	2018-02-26	Espacenet
GE	GEP20186866B	B	2018-06-25	Espacenet
HK	HK1253911A1	A1	2019-07-05	Espacenet
HR	HRP20171457T1	T1	2017-11-03	Espacenet
HR	HRP20260026T1	T1	2026-02-27	Espacenet
HR	HRP20260461T1	T1	2026-05-08	Espacenet
HU	HUE036664T2	T2	2018-07-30	Espacenet
IL	IL229169B	B	2020-06-30	Espacenet
IL	IL272237A	A	2020-02-27	Espacenet
IL	IL272237B	B	2022-05-01	Espacenet
IL	IL274846A	A	2020-07-30	Espacenet
IL	IL274846B1	B1	2024-12-01	Espacenet
IL	IL274846B2	B2	2025-04-01	Espacenet
IL	IL290848A	A	2022-04-01	Espacenet
IL	IL290849A	A	2022-04-01	Espacenet
IL	IL305583A	A	2023-10-01	Espacenet
IL	IL305583B1	B1	2025-12-01	Espacenet
IL	IL305583B2	B2	2026-04-01	Espacenet
JP	JP2014515763A	A	2014-07-03	Espacenet
JP	JP6190359B2	B2	2017-08-30	Espacenet
JP	JP2017137353A	A	2017-08-10	Espacenet
JP	JP6467457B2	B2	2019-02-13	Espacenet
JP	JP2019052191A	A	2019-04-04	Espacenet
JP	JP6751450B2	B2	2020-09-02	Espacenet
JP	JP2020180163A	A	2020-11-05	Espacenet
JP	JP7107997B2	B2	2022-07-27	Espacenet
JP	JP2022132430A	A	2022-09-08	Espacenet
JP	JP7636651B2	B2	2025-02-27	Espacenet
JP	JP2025061332A	A	2025-04-10	Espacenet
KR	KR20140145952A	A	2014-12-24	Espacenet
KR	KR101875155B1	B1	2018-07-09	Espacenet
KR	KR20170056713A	A	2017-05-23	Espacenet
KR	KR101884406B1	B1	2018-08-02	Espacenet
KR	KR20180080354A	A	2018-07-11	Espacenet
KR	KR102014512B1	B1	2019-08-26	Espacenet
KR	KR20190100451A	A	2019-08-28	Espacenet
KR	KR102136208B1	B1	2020-07-21	Espacenet
KR	KR20200088517A	A	2020-07-22	Espacenet
KR	KR102308938B1	B1	2021-10-01	Espacenet
KR	KR20210120144A	A	2021-10-06	Espacenet
KR	KR102493433B1	B1	2023-01-27	Espacenet
KR	KR102493433B9	B9	2023-09-01	Espacenet
KR	KR20230021758A	A	2023-02-14	Espacenet
KR	KR20250093426A	A	2025-06-24	Espacenet
LT	LT2704742T	T	2017-10-25	Espacenet
LT	LT3311834T	T	2026-05-11	Espacenet
LT	LT4403579T	T	2026-01-26	Espacenet
ME	ME02858B	B	2018-04-20	Espacenet
MX	MX2013012725A	A	2013-12-06	Espacenet
MX	MX354101B	B	2018-02-13	Espacenet
MX	MX2019009244A	A	2019-09-13	Espacenet
MX	MX384203B	B	2025-03-14	Espacenet
MX	MX2021008112A	A	2022-06-02	Espacenet
MX	MX367097B	B	2019-08-05	Espacenet
MY	MY188820A	A	2022-01-05	Espacenet
NZ	NZ617340A	A	2015-12-24	Espacenet
PE	PE20141672A1	A1	2014-11-26	Espacenet
PH	PH12013502237A1	A1	2014-01-06	Espacenet
PH	PH12018502221A1	A1	2019-10-28	Espacenet
PH	PH12018502221B1	B1	2023-05-10	Espacenet
PH	PH12019501662A1	A1	2021-03-15	Espacenet
PL	PL2704742T3	T3	2018-01-31	Espacenet
PL	PL3311834T3	T3	2026-05-25	Espacenet
PL	PL4403579T3	T3	2026-03-09	Espacenet
PT	PT2704742T	T	2017-11-15	Espacenet
PT	PT3311834T	T	2026-04-21	Espacenet
PT	PT4403579T	T	2026-02-05	Espacenet
RS	RS56429B1	B1	2018-01-31	Espacenet
RS	RS67634B1	B1	2026-02-27	Espacenet
RS	RS68003B1	B1	2026-05-29	Espacenet
SG	SG194730A1	A1	2013-12-30	Espacenet
SI	SI2704742T1	T1	2017-12-29	Espacenet
SI	SI3311834T1	T1	2026-06-30	Espacenet
SI	SI4403579T1	T1	2026-02-27	Espacenet
SM	SMT201700515T1	T1	2018-01-11	Espacenet
SM	SMT202600024T1	T1	2026-03-09	Espacenet
SM	SMT202600188T1	T1	2026-05-12	Espacenet
TN	TN2013000455A1	A1	2015-03-30	Espacenet
TW	TW201300128A	A	2013-01-01	Espacenet
TW	TWI638661B	B	2018-10-21	Espacenet
TW	TW201813665A	A	2018-04-16	Espacenet
TW	TWI698254B	B	2020-07-11	Espacenet
TW	TW201940195A	A	2019-10-16	Espacenet
TW	TWI723339B	B	2021-04-01	Espacenet
TW	TW202133878A	A	2021-09-16	Espacenet
TW	TWI799757B	B	2023-04-21	Espacenet
TW	TW202317193A	A	2023-05-01	Espacenet
TW	TWI832619B	B	2024-02-11	Espacenet
TW	TW202434293A	A	2024-09-01	Espacenet
TW	TWI907924B	B	2025-12-11	Espacenet
UA	UA112984C2	C2	2016-11-25	Espacenet
US	US2014341885A1	A1	2014-11-20	Espacenet
US	US10040855B2	B2	2018-08-07	Espacenet
US	US2020377601A1	A1	2020-12-03	Espacenet
US	US11560434B2	B2	2023-01-24	Espacenet
US	US2021340261A1	A1	2021-11-04	Espacenet
US	US12286479B2	B2	2025-04-29	Espacenet
US	US2018327497A1	A1	2018-11-15	Espacenet
US	US2018346578A1	A1	2018-12-06	Espacenet
US	US2023312727A1	A1	2023-10-05	Espacenet
US	US20250034263A1	A1	2025-01-30	Espacenet
US	US20260193360A1	A1	2026-07-09	Espacenet
US	US20260201042A1	A1	2026-07-16	Espacenet
US	US20260209361A1	A1	2026-07-23	Espacenet
US	US20260274963A1	A1	2026-09-17	Espacenet
US	US20260274964A1	A1	2026-09-17	Espacenet
US	US20260317427A1	A1	2026-10-15	Espacenet
UY	UY34054A	A	2012-11-30	Espacenet
WO	WO2012151247A2	A2	2012-11-08	Espacenet
WO	WO2012151247A3	A3	2013-02-28	Espacenet
ZA	ZA201308168B	B	2018-11-28	Espacenet
ZA	ZA201707310B	B	2022-04-28	Espacenet

Official File Inspection EPC Art. 128 Public Dossier

Complete European Patent Register Dossier (148 Total Documents)

The full inspection file for Application EP24167554 contains 148 total documents, including all notices of opposition, proprietor counter-statements, examination communications, third-party observations, and procedural forms. Below are all major recorded procedural filings and publication specifications.

Open 148-Doc Register Dossier

Recorded Filings & Patent Specifications

Official publication specifications, opposition filings, proprietor replies, and procedural submissions.

35 Filings Listed

European Patent Specification - Granted Patent (B1)

Publication Specification

Date: 2025-12-10 Procedure: Grant EP4403579B1

View / Download PDF

Official European Patent Register Full Dossier

Publication Specification

Date: 2025-12-10 Procedure: All Proceedings (Examination & Opposition) EP24167554

View / Download PDF

European Search Report (A3)

Publication Specification

Date: 2024-10-16 Procedure: Publication EP4403579A3

View / Download PDF

European Patent Application without Search Report (A2)

Publication Specification

Date: 2024-07-24 Procedure: Publication EP4403579A2

View / Download PDF

Change: Communication of a notice of opposition and request to file observations + time limit

Dossier Filing

Date: 2026-10-20 Procedure: Opposition EPIDOSCOBS2

Inspect on Register

Change - representative

Dossier Filing

Date: 2026-10-14 Procedure: Examination EPIDOS FREP

Inspect on Register

Invitation to proprietor to file observations on the notice of opposition

Procedural Step

Date: 2026-09-22 Procedure: Opposition OBSO

Inspect on Register

New entry: Communication of a notice of opposition and request to file observations + time limit

Dossier Filing

Date: 2026-09-21 Procedure: Opposition EPIDOSNOBS2

Inspect on Register

Opposition filed

Dossier Filing

Date: 2026-09-18 Procedure: Opposition 0009260

Inspect on Register

Change - opposition data/opponent's data or that of the opponent's representative

Dossier Filing

Date: 2026-09-18 Procedure: Opposition 0009299OPPO

Inspect on Register

Opposition filed

Dossier Filing

Date: 2026-09-11 Procedure: Opposition 0009260

Inspect on Register

Lapse of the patent in a contracting state

Dossier Filing

Date: 2026-05-22 Procedure: Examination 0009250

Inspect on Register

FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY

Patent Abstract / Summary

IPC Classifications

Priority Claims

Designated Contracting States (38 EPC States)

Parties & Representation

Applicants

Inventors (9)

Representatives / Agents

Key Procedural Dates

Patent Oppositions

Abel & Imray LLP

Lepthien, Sandra

Fresenius Kabi SwissBiosim GmbH

Camulon Ltd

Advanz Pharma Services (UK) Ltd

Legal Status & Event History

Patent & Non-Patent Citations

Cited Patent Documents

Non-Patent Scientific Literature (NPL)

Worldwide Patent Family

Complete European Patent Register Dossier (148 Total Documents)

Recorded Filings & Patent Specifications

European Patent Specification - Granted Patent (B1)

Official European Patent Register Full Dossier

European Search Report (A3)

European Patent Application without Search Report (A2)

Change: Communication of a notice of opposition and request to file observations + time limit

Change - representative

Invitation to proprietor to file observations on the notice of opposition

New entry: Communication of a notice of opposition and request to file observations + time limit

Opposition filed

Change - opposition data/opponent's data or that of the opponent's representative

Opposition filed

Lapse of the patent in a contracting state

Change - inventor

(Expected) grant

New entry: Receipt of the translation of the claim(s)

New entry: Payment of fee for grant

New entry: Payment of fee for publishing/printing

New entry: Communication of intention to grant a patent

Intention to grant the patent

Change - classification

New entry: Renewal fee paid

Renewal fee payment

The date on which the examining division becomes responsible, has been established

Request for examination filed

Amendment by applicant

Amendments

Date on which the examining division has become responsible

Change - classification

Publication of search report

Publication in section I.1 EP Bulletin

Change - representative

New entry: Renewal fee paid

Renewal fee payment

Language of the procedure

International searching authority